Receptor News and Research

RSS

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.

9 Apr 2010

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Using T cells primed for the infectious disease toxoplasmosis, Whitehead Institute researchers have created novel mouse models of the immune system that more accurately reflect how immune cells actually respond to pathogens in their presence.

9 Apr 2010

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.

9 Apr 2010

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

8 Apr 2010

Researchers develop new mouse model of VUR to study chronic kidney disease in children

Kidney damage associated with chronic reflux is the fourth leading cause of chronic kidney disease and is the most common cause of severe hypertension in children. Doctors and researchers at Nationwide Children's Hospital have developed a new mouse model of vesicoureteral reflux, a common childhood condition that can lead to chronic kidney disease in children.

7 Apr 2010

Non-conscious, learning systems of the brain simpler and evolutionarily older, study substantiates

A new study from the Swedish medical university Karolinska Institutet provides evidence that basic human learning systems use areas of the brain that also exist in the most primitive vertebrates, such as certain fish, reptiles and amphibians. The study involved an investigation into the limbic striatum, one of the evolutionarily oldest parts of the brain, and the ability to learn movements, consciously and unconsciously, through repetition.

7 Apr 2010

Officials of Kylin Therapeutics receive an issued patent from USPTO

Officials of Kylin Therapeutics Inc., a leading RNAi company, announced this week that they received an issued patent from the U.S. Patent and Trademark Office.

7 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine -targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research.

6 Apr 2010

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces β-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine.

5 Apr 2010

New report questions the kinetics of T cell receptors

T cell receptors are among the most important molecules in the immune system because of their role in recognizing the antigens that signal such threats as viruses and cancer. The receptors must also distinguish these threats from the body's own cells to avoid triggering an unwanted immune system response.

5 Apr 2010

Kyto Biopharma enters agreement with Targeted Payload Therapeutics

Kyto Biopharma Inc., is a Florida biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

3 Apr 2010

Study could aid in developing new, effective treatments for prostate cancer

Van Andel Research Institute (VARI) scientists have determined how two proteins required for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved treatments for the disease.

3 Apr 2010

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

3 Apr 2010

Harnessing body's own natural killer cells to battle cancer in children

Work underway at St. Jude Children's Research Hospital seeks to harnesses the body's own immune cells known as natural killer, or NK, cells to help children battle cancer. NK cells are the immune system's warriors. The cells circulate widely in the body, armed with proteins, called enzymes, capable of delivering a deadly one-two punch to viruses and cancer cells.

3 Apr 2010

Scientists provide first-ever glimpse of HIV protein structure

Scientists from the California Institute of Technology (Caltech) have provided the first-ever glimpse of the structure of a key protein-gp120-found on the surface of a specific subgroup of the human immunodeficiency virus, HIV-1.

3 Apr 2010

Study promises new combination cancer therapy for drug resistance

Results reported in the April 2nd issue of the journal Cell, a Cell Press publication, reveal a new source for the drug resistance that crops up all too often and quickly in the tumors of cancer patients undergoing therapy.

2 Apr 2010

Sunshine vitamin cures common health problems

What do obesity, heart disease, depression, diabetes, and fibromyalgia have in common? The answer is vitamin D deficiency. More than 200 million Americans lack this essential vitamin and as a result suffer from a host of daily annoyances, chronic conditions, and even life-threatening illnesses.

2 Apr 2010

Conventional analgesics to drive acute pain market over the next decade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018, the launches and uptake of reformulations of conventional analgesics will drive annual three percent growth in the acute pain drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

1 Apr 2010

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.

1 Apr 2010

Receptor News and Research

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Researchers develop new mouse model of VUR to study chronic kidney disease in children

Non-conscious, learning systems of the brain simpler and evolutionarily older, study substantiates

Officials of Kylin Therapeutics receive an issued patent from USPTO

StockPreacher.com releases investment report on Repros Therapeutics

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

New report questions the kinetics of T cell receptors

Kyto Biopharma enters agreement with Targeted Payload Therapeutics

Study could aid in developing new, effective treatments for prostate cancer

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

Harnessing body's own natural killer cells to battle cancer in children

Scientists provide first-ever glimpse of HIV protein structure

Study promises new combination cancer therapy for drug resistance

Sunshine vitamin cures common health problems

Conventional analgesics to drive acute pain market over the next decade

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News